Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Cells ; 9(1)2019 Dec 25.
Article in English | MEDLINE | ID: mdl-31881755

ABSTRACT

Recent studies provide evidence to support that cluster of differentiation 38 (CD38) and CD157 meaningfully act in the brain as neuroregulators. They primarily affect social behaviors. Social behaviors are impaired in Cd38 and Cd157 knockout mice. Single-nucleotide polymorphisms of the CD38 and CD157/BST1 genes are associated with multiple neurological and psychiatric conditions, including autism spectrum disorder, Parkinson's disease, and schizophrenia. In addition, both antigens are related to infectious and immunoregulational processes. The most important clues to demonstrate how these molecules play a role in the brain are oxytocin (OT) and the OT system. OT is axo-dendritically secreted into the brain from OT-containing neurons and causes activation of OT receptors mainly on hypothalamic neurons. Here, we overview the CD38/CD157-dependent OT release mechanism as the initiation step for social behavior. The receptor for advanced glycation end-products (RAGE) is a newly identified molecule as an OT binding protein and serves as a transporter of OT to the brain, crossing over the blood-brain barrier, resulting in the regulation of brain OT levels. We point out new roles of CD38 and CD157 during neuronal development and aging in relation to nicotinamide adenine dinucleotide+ levels in embryonic and adult nervous systems. Finally, we discuss how CD38, CD157, and RAGE are crucial for social recognition and behavior in daily life.


Subject(s)
ADP-ribosyl Cyclase 1/metabolism , ADP-ribosyl Cyclase/metabolism , Antigens, CD/metabolism , Receptor for Advanced Glycation End Products/metabolism , Social Behavior , Animals , Autism Spectrum Disorder/genetics , Autism Spectrum Disorder/metabolism , Biomarkers , Brain/metabolism , Calcium Signaling , Enzyme Activation , GPI-Linked Proteins/metabolism , Gene Expression Regulation, Developmental , Genetic Association Studies , Humans , Immunohistochemistry , Mice, Knockout , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , Oxytocin , Polymorphism, Single Nucleotide , RNA, Messenger/genetics , Receptor for Advanced Glycation End Products/genetics , TRPM Cation Channels/metabolism
2.
Mass Spectrom (Tokyo) ; 6(Spec Iss 2): S0069, 2017.
Article in English | MEDLINE | ID: mdl-28948132

ABSTRACT

We compared two ionization methods, matrix assisted laser desorption/ionization (MALDI) and nanoparticle assisted laser desorption/ionization (Nano-PALDI) mass spectrometry (MS), for the analysis of amino acids derivatized with Py-Tag™ that consists pyrylium-based compound. Py-Tag is a useful stable derivatization reagent due to wide mass differences (using 13C as the sole stable labelling isotope). For Py-Tag labelled lysine, sensitive signals that showed less noise with a ten times higher sensitivity, showed a wider mass difference by Nano-PALDI MS compared to MALDI MS.

3.
Biomed Res Int ; 2015: 720250, 2015.
Article in English | MEDLINE | ID: mdl-25654121

ABSTRACT

Yaks have adapted to high altitude and they do not develop hypoxic pulmonary hypertension. Although we previously identified the important role of augmented nitric oxide synthase activity in the yak pulmonary circulatory system, evidence of the direct involvement of Rho-kinase as a basal vascular tone regulator is lacking. Four domesticated male pure-bred yaks and four bulls that were born and raised at an altitude of 3000 m in the Tien-Shan mountains were studied at an altitude of 3,100 m. Mean pulmonary artery pressure (mPAP) was measured before and after fasudil (60 mg in 20 mL of saline) was intravenously administered using a Swan-Ganz catheter at a rate of 3.3 mL/min for 30 min. Fasudil decreased mPAP in bulls from 67.8±14.9 to 32.3±5.3 mmHg (P < 0.05) after 15 min and the level was maintained for 30 min, but it merely blunted mPAP in yaks from 28.2±4.5 to 25.1±11.1 and 23.2±2.7 mmHg after 5 and 30 min, respectively. These findings comprise the first evidence of a modest role of Rho-kinase in the maintenance of pulmonary artery pressure in the yak.


Subject(s)
Pulmonary Circulation , rho-Associated Kinases/metabolism , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/administration & dosage , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Altitude , Animals , Blood Pressure/drug effects , Cattle , Enzyme Activation/drug effects , Hemodynamics/drug effects , Male , Pulmonary Artery/drug effects , Pulmonary Artery/enzymology , Pulmonary Artery/physiology , Pulmonary Circulation/drug effects
4.
Int J Oncol ; 42(2): 565-73, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23242308

ABSTRACT

Cell motility proceeds by cycles of edge protrusion, adhesion and retraction. Whether these functions are coordinated by biochemical or biomechanical processes is unknown. Tumor invasion and metastasis is directly related to cell motility. We showed that stimulation of proteinase-activated receptor-1 (PAR1) can trigger an array of responses that would promote tumor cell growth and invasion. Thus, we examined aspects of PAR1 activation related to cell morphological change that might contribute to cell motility. We established a PAR1 stably transfected MKN45 gastric cancer cell line (MKN45/PAR1). We examined morphological changes, Rho family activation and overexpression of cytoskeletal protein in cells exposed to PAR1 agonists (α-thrombin and TFLLR-NH2). MKN45/PAR1 grows with an elongated and polarized morphology, extending pseudopodia at the leading edge. However, in the presence of PAR1 antagonist, MKN45/PAR1 did not show any changes in cell shape upon addition of either α-thrombin or TFLLR-NH2. Activated PAR1 induced RhoA and Rac1 phosphorylation, and subsequent overexpression of myosin IIA and filamin B which are stress fiber components that were identified by PMF analysis of peptide mass data obtained by MALDI-TOF/MS measurement. Upon stimulation of MKN45/PAR1 for 24 h with either α-thrombin or TFLLR-NH2, the distribution of both myosin IIA and filamin B proteins shifted to being distributed throughout the cytoplasm to the membrane, with more intense luminescence signals than in the absence of stimulation. These results demonstrate that PAR1 activation induces cell morphological change associated with cell motility via Rho family activation and cytoskeletal protein overexpression, and has a critical role in gastric cancer cell invasion and metastasis.


Subject(s)
Cell Movement/genetics , Neoplasm Invasiveness/genetics , Receptor, PAR-1/metabolism , Stomach Neoplasms/genetics , Cell Line, Tumor , Cytoskeleton/metabolism , Filamins/metabolism , Gene Expression Regulation, Neoplastic/genetics , Humans , Neoplasm Metastasis/genetics , Neoplasm Metastasis/pathology , Nonmuscle Myosin Type IIA/metabolism , Phosphorylation , Receptor, PAR-1/antagonists & inhibitors , Receptor, PAR-1/genetics , Stomach Neoplasms/pathology , rac1 GTP-Binding Protein/metabolism , rhoA GTP-Binding Protein/metabolism
5.
BMC Cancer ; 10: 443, 2010 Aug 19.
Article in English | MEDLINE | ID: mdl-20723226

ABSTRACT

BACKGROUND: In addition to regulating platelet function, the G protein-coupled sub-family member Proteinase-activated receptor-1 (PAR1) has a proposed role in the development of various cancers, but its exact role and mechanism of action in the invasion, metastasis, and proliferation process in gastric cancer have yet to be completely elucidated. Here, we analyzed the relationship between PAR1 activation, proliferation, invasion, and the signaling pathways downstream of PAR1 activation in gastric cancer. METHODS: We established a PAR1 stably transfected MKN45 human gastric cancer cell line (MKN45/PAR1) and performed cell proliferation and invasion assays employing this cell line and MKN28 cell line exposed to PAR1 agonists (alpha-thrombin and TFLLR-NH2). We also quantified NF-kappaB activation by electrophoretic mobility shift assay (EMSA) and the level of Tenascin-C (TN-C) expression in conditioned medium by ELISA of MKN45/PAR1 following administration of alpha-thrombin. A high molecular weight concentrate was derived from the resultant conditioned medium and subsequent cultures of MKN45/PAR1 and MKN28 were exposed to the resultant concentrate either in the presence or absence of TN-C-neutralizing antibody. Lysates of these subsequent cells were probed to quantify levels of phospholyrated Epidermal Growth Factor Receptor (EGFR). RESULT: PAR1 in both PAR1/MKN45 and MKN28 was activated by PAR1 agonists, resulting in cell proliferation and matrigel invasion. We have shown that activation of NF-kappaB and EGFR phosphorylation initially were triggered by the activation of PAR1 with alpha-thrombin. Quantitative PCR and Western blot assay revealed up-regulation of mRNA and protein expression of NF-kappaB target genes, especially TN-C, a potential EGFR activator. The suppressed level of phosphorylated EGFR, observed in cells exposed to concentrate of conditioned medium in the presence of TN-C-neutralizing antibody, identifies TN-C as a putative autocrine stimulatory factor of EGFR possibly involved in the sustained PAR1 activation responses observed. CONCLUSION: Our data indicate that in gastric carcinoma cells, PAR1 activation can trigger an array of responses that would promote tumor cell growth and invasion. Over expression of NF-kappaB, EGFR, and TN-C, are among the effects of PAR1 activation and TN-C induces EGFR activation in an autocrine manner. Thus, PAR1 is a potentially important therapeutic target for the treatment of gastric cancer.


Subject(s)
Cell Movement , Cell Proliferation , Receptor, PAR-1/metabolism , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Blotting, Western , Cell Line, Tumor , Culture Media, Conditioned/pharmacology , Electrophoretic Mobility Shift Assay , Enzyme-Linked Immunosorbent Assay , ErbB Receptors/genetics , ErbB Receptors/metabolism , Flow Cytometry , Humans , Immunoenzyme Techniques , NF-kappa B/genetics , NF-kappa B/metabolism , Neoplasm Invasiveness , Phosphorylation/drug effects , RNA, Messenger/genetics , Receptor, PAR-1/agonists , Receptor, PAR-1/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tenascin/genetics , Tenascin/metabolism , Thrombin/pharmacology
6.
J Neurooncol ; 76(3): 219-25, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16283438

ABSTRACT

Vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis. Interferons (IFNs) have been widely used in the treatment of malignant or recurrent gliomas with only marginal benefit. The association between IFNs and VEGF expression remains unclear and should be an intensively investigated subject. The present study therefore examined the effects of different types of IFNs on VEGF expression in human T98G, A172 and U251 glioblastoma cells by quantitative RT-PCR and ELISA. Both type I (alpha, beta) and type II (gamma) IFNs upregulated VEGF expression in a cell-specific but p53-independent manner. Actinomycin D experiments demonstrated that IFNs did not alter VEGF mRNA stability. In contrast, induction of VEGF mRNA by IFNs was blocked by the protein synthesis inhibitor cycloheximide. Interestingly, cycloheximide also blocked IFN-induced activation of the p44/p42 mitogen-activated protein kinase, which was partially required for induction of VEGF by IFNs. These findings suggest that VEGF might be an indirect target gene of IFNs, and might provide insights into therapeutic applications of IFNs against angiogenesis-dependent tumors.


Subject(s)
Brain Neoplasms/metabolism , Glioblastoma/metabolism , Interferons/pharmacology , Tumor Suppressor Protein p53/metabolism , Vascular Endothelial Growth Factor A/drug effects , Blotting, Western , Cell Line, Tumor , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Enzyme-Linked Immunosorbent Assay , Humans , Mitogen-Activated Protein Kinases/drug effects , Neovascularization, Pathologic/metabolism , Protein Synthesis Inhibitors/pharmacology , RNA, Messenger/analysis , RNA, Messenger/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , Vascular Endothelial Growth Factor A/biosynthesis
7.
J Neurooncol ; 72(3): 217-23, 2005 May.
Article in English | MEDLINE | ID: mdl-15937643

ABSTRACT

Overexpression of the angiogenic enzyme thymidine phosphorylase (TP) in tumor cells and/or infiltrating macrophages correlates with increased microvessel density and poor prognosis in various tumor types including glioma. The present study examined how the TP gene expression is regulated by different types of interferons (IFNs) in human T98G and A172 glioblastoma cells. Both type I (alpha, beta) and type II (gamma) IFNs upregulated TP mRNA and protein expression while inhibiting cell proliferation. IFN-induced TP mRNA accumulation was not inhibited by the protein synthesis inhibitor cycloheximide, but was strongly blocked by the transcription inhibitor actinomycin D, as well as by transcription factor decoy oligodeoxynucleotides containing the putative IFN response element or the gamma-activated sequence in the TP promoter. The Janus kinase (JAK) inhibitor AG-490 blocked both IFN-induced STAT1 (signal transducers and activators of transcription 1) phosphorylation and TP expression. All IFNs increased the stability of TP mRNA as well. In addition, IFN-evoked TP enzyme activity enhanced the cytotoxicity of 5-fluorouracil (5-FU). These findings indicate that TP expression may be upregulated by IFNs via the JAK-STAT signaling pathway and both transcriptional and posttranscriptional mechanisms. Combined treatment with IFN and 5-fluorouracil may be a useful therapeutic strategy for malignant gliomas.


Subject(s)
Antineoplastic Agents/pharmacology , Brain Neoplasms/metabolism , DNA-Binding Proteins/genetics , Glioblastoma/metabolism , Interferons/pharmacology , Protein-Tyrosine Kinases/genetics , RNA, Messenger/metabolism , Thymidine Phosphorylase/biosynthesis , Trans-Activators/genetics , Transcriptional Activation/physiology , Antimetabolites, Antineoplastic/pharmacology , Blotting, Western , Brain Neoplasms/enzymology , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Synergism , Fluorouracil/pharmacology , Glioblastoma/enzymology , Half-Life , Humans , Indicators and Reagents , Janus Kinase 1 , RNA Processing, Post-Transcriptional , Reverse Transcriptase Polymerase Chain Reaction , STAT1 Transcription Factor , Tetrazolium Salts , Thiazoles , Up-Regulation/drug effects
8.
J Surg Oncol ; 87(4): 174-81, 2004 Sep 15.
Article in English | MEDLINE | ID: mdl-15334632

ABSTRACT

BACKGROUND: Heparanase is considered to play an important role in tumor invasion and hematogenous metastasis. The aim of this study was to determine the expression of heparanase in colorectal cancer to evaluate its prognostic value. METHODS: We analyzed heparanase mRNA derived from 130 colorectal cancer patients by reverse transcription polymerase chain reaction (PCR), compared its expression with clinicopathologic factors, and performed statistical analysis. To investigate the relationship between heparanase expression and tumor angiogenesis, 81 primary colorectal tumors were immunostained by use of a monoclonal anti-CD34 antibody. RESULTS: Thirty three of 130 cancer tissues overexpressed heparanase. There were significant correlations between heparanase expression and serosal invasion, venous invasion, and liver metastasis. Multivariate analyzes revealed that heparanase mRNA overexpression was a significant independent risk factor for hematogenous metastasis in colorectal cancer. Among 104 patients who underwent curative resection, heparanase expression correlated with a high recurrence. The 5-year survival rate was 84.6% for patients with heparanase negative tumors, and 47.7% for those with heparanase overexpression; these differences between two groups of patients were significant. In multivariate analysis using the Cox regression model, heparanese expression emerged as an independent prognostic indicator. Moreover, the tumor angiogenesis of heparanase-positive tumors determined with a monoclonal anti-CD34 antibody was significantly higher than that of heparanase-negative tumors. CONCLUSIONS: These results indicated that Heparanase expression may be an important role in invasion and hematogenous metastasis, and may be a biologic marker of prognostic significance in colorectal cancer patients.


Subject(s)
Colorectal Neoplasms/enzymology , Colorectal Neoplasms/pathology , Glucuronidase/biosynthesis , Neoplastic Cells, Circulating/metabolism , Neovascularization, Pathologic/enzymology , Cell Line, Tumor , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/mortality , Glucuronidase/genetics , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Humans , Liver Neoplasms/secondary , Multivariate Analysis , Neoplasm Invasiveness , Peritoneal Neoplasms/epidemiology , Prognosis , Proportional Hazards Models , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate
9.
Oral Oncol ; 40(4): 390-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14969818

ABSTRACT

Recent studies have demonstrated that a caspase-activated deoxyribonuclease (CAD) causes DNA degradation in nuclei after treatment of cells with caspase-3. In this study, we evaluated the effect of CAD overexpression on tumor cells treated with a chemotherapeutic agent in vitro and in vivo. In an in vitro study, we transfected mouse fibroblast L cells with a vector encoding mouse CAD and evaluated the therapeutic potential of CAD gene transfer to L cells treated with cisplatin (CDDP). In an in vivo study, percutaneous transfer of the mouse CAD gene by particle-mediated (gene gun) delivery caused overexpression of CAD in mouse squamous cell carcinoma (SCC). Our results showed that a combined treatment of CDDP and exogenous introduction of the CAD gene into tumor cells in vitro and in vivo arrested tumor growth and induced apoptosis. These results suggest that combined treatment of CDDP and exogenous CAD expression might be a useful strategy for cancer therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Carcinoma, Squamous Cell/therapy , Cisplatin/pharmacology , Deoxyribonucleases/genetics , Genetic Therapy/methods , Head and Neck Neoplasms/therapy , Animals , Apoptosis/genetics , Biolistics , Carcinoma, Squamous Cell/pathology , Cells, Cultured , Combined Modality Therapy , Deoxyribonucleases/metabolism , Fibroblasts/enzymology , Fibroblasts/ultrastructure , Genetic Vectors , Head and Neck Neoplasms/pathology , Mice , Mice, Inbred C3H , Neoplasm Transplantation , Transfection
10.
Endocr J ; 50(5): 579-87, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14614214

ABSTRACT

Oxytocin receptor (OTR) mRNA levels in the uterus dramatically increase in the near term human and rat. Estrogen is believed to be a potent stimulator of OTR mRNA expression. However, estrogen does not stimulate rat OTR mRNA expression on day 18 of pregnancy or in progesterone-treated rats. Thus, the regulation of uterine responsiveness to estrogen in the near term rat appears to be an important mediator of estrogen action. To determine the effect of altering uterine responsiveness to estrogen on OTR induction, uterine ERalpha and ER beta mRNA levels were examined by competitive RT-PCR in pregnant and parturient rats, progesterone-treated ovariectomized (OVX) virgin rats and OVX pregnant rats. In pregnant and parturient rats, OTR mRNA levels were highest at 2200-2230 h on day 21 of pregnancy (P21pm) and during labor when compared with other groups. ERalpha mRNA levels significantly increased during labor compared with days 15-21 of pregnancy. Compared with control animals, ERalpha mRNA levels decreased significantly in OVX virgin rats implanted with tubes containing progesterone for one week; 24 h following the removal of the progesterone tubes, ERalpha mRNA levels were found to be similar to control levels. Estrogen treatment following OVX on day 18 of pregnancy caused increased OTR mRNA levels, whereas ovariectomy alone increased ERbeta mRNA but not ERalpha mRNA. Results from the present study suggest that ERalpha and ERbeta mRNA expressions are differentially regulated in the rat uterus. Moreover, during spontaneous labor our findings appear to suggest that ERalpha plays a more prominent role than ERbeta in mediating estrogen action in the induction of uterine OTR mRNA before labor.


Subject(s)
Labor, Obstetric/metabolism , Pregnancy, Animal/metabolism , Receptors, Estrogen/metabolism , Receptors, Oxytocin/metabolism , Uterus/metabolism , Animals , Estradiol/pharmacology , Estrogen Receptor alpha , Estrogen Receptor beta , Female , Gene Expression Regulation , Ovariectomy , Pregnancy , Progesterone/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Estrogen/genetics , Receptors, Oxytocin/genetics , Uterus/drug effects
11.
Pulm Pharmacol Ther ; 15(1): 25-33, 2002.
Article in English | MEDLINE | ID: mdl-11969361

ABSTRACT

To provide evidence that pulmonary endothelial cells exposed to 9,10-epoxy-12-octadecenoate (Lx) produce nitric oxide (NO) and superoxide anion (O(2)(*-), we measured NO production, using a NO chemiluminescence analyzer, and nitric oxide synthase (NOS) activity, monitoring the conversion of L- [14C] arginine to L- [14C] citrulline, and O(2)(*-) by a fluorescence assay using a fluorescence spectrophotometer with hydroethidine (HE) in human pulmonary artery endothelial cells (HPAEC). NO production and eNOS were increased significantly when HPAEC were incubated with 10 microM Lx, and this effect was inhibited by L-NMMA or in the absence of extracellular Ca2+. Addition of 10 mM HE to the cell suspension spontaneously and continuously caused a subtle increase in fluorescence intensity, due to intracellular oxidation of HE to ethidium bromide (EB). Treatment of the cell suspension with Lx after the addition of HE exerted a dose-dependent increase in intracellular EB fluorescence. Pre-treatment with allopurinol, a xanthine oxidase inhibitor, decreased the intracellular EB fluorescence by 54% in HPAEC incubated with 100 microM Lx. These results show that Lx induces NO production via activation of eNOS and O(2)(*-) production in endothelial cells via activation of cellular xanthine oxidase. Thus, Lx is a bioactive lipid.


Subject(s)
Endothelium, Vascular/drug effects , Exotoxins/pharmacology , Immunosuppressive Agents/pharmacology , Nitric Oxide Synthase/metabolism , Nitric Oxide/biosynthesis , Superoxides/metabolism , Cells, Cultured , Endothelium, Vascular/metabolism , Enzyme Activation/drug effects , Humans , Pulmonary Artery/drug effects , Pulmonary Artery/metabolism , Xanthine Oxidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...